Impact of Short-course Colchicine Versus Placebo After Pulmonary Vein Isolation (IMPROVE-PVI Pilot)
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 202 participants.
Also called NCT04160117
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 202 participants
- Registry
-
NCT04160117
-
- Other papers using this trial's data
- Colchicine to Prevent Atrial Fibrillation Recurrence After Catheter Ablation: A Randomized, Placebo-Controlled Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Canada
- Registry status
- Completed
Technical summary
Registry record NCT04160117. Randomized; quadruple masking; primary purpose treatment. Start 2020-01-14 (actual); primary completion 2022-05-30 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Impact of Short-course Colchicine Versus Placebo After Pulmonary Vein Isolation (IMPROVE-PVI Pilot)
- Condition
- Atrial Fibrillation
- Condition
- Recurrence
- Intervention (Drug)
- Colchicine 0.6 mg
- Intervention (Drug)
- Matching placebo
- Lead sponsor
- Population Health Research Institute
Record details
- Record id
cardio:ct-nct04160117- Content hash
a927e694431d32dcec3263736e24df6db768c8c7a31d61051963a97e9ef3dac8